Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Pacini, F ^a   Castagna, M G ^a   Brilli, L ^a   Pentheroudakis, G ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; CISPLATIN; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GEFITINIB; IODINE 131; LEVOTHYROXINE; MOTESANIB; PACLITAXEL; RECOMBINANT THYROTROPIN; SORAFENIB; SUNITINIB; THYROGLOBULIN; VANDETANIB;

ANAPLASTIC CARCINOMA; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER STAGING; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISTANT METASTASIS; EUROPE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; NEEDLE BIOPSY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROTROPIN BLOOD LEVEL; TUMOR ABLATION;

ADOLESCENT; BIOPSY, NEEDLE; CALCITONIN; CHILD; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; PROTEIN-TYROSINE KINASES; RECOMBINANT PROTEINS; REMISSION INDUCTION; RISK ASSESSMENT; THYROID FUNCTION TESTS; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; THYROXINE; TREATMENT OUTCOME;

EID: 77954337467     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq190     Document Type: Article

References (46)

1. Liu S, Semenciw R, Ugnat AM, Mao Y. Increasing thyroid cancer incidence in Canada, 1970-1996: time trends and age-period-cohort effects. Br J Cancer 2001; 85: 1335-1339.
2. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 2009; 115: 3801-3807.
3. Reynolds RM, Weir J, Stockton DL et al. Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin Endocrinol 2005; 62: 156-162.
4. Colonna M, Danzon A, Delafosse P et al. Cancer prevalence in France: time trend, situation in 2002 and extrapolation to 2012. Eur J Cancer 2008; 44: 115-122.
5. Fahey TJ 3rd, Reeve TS, Delbridge L. Increasing incidence and changing presentation of thyroid cancer over a 30-year period. Br J Surg 1995; 82: 518-520.
6. Galanti MR, Hansson L, Bergström R et al. Diet and the risk of papillary and follicular thyroid carcinoma: a population-based case-control study in Sweden and Norway. Cancer Causes Control 1997; 8: 205-214.
7. Leenhardt L, Bernier MO, Boin-Pineau MH et al. Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol 2004; 150: 133-139.
8. Nagataki S, Aashizawa KS. Cause of childhood thyroid cancer after the chernobyl accident. Thyroid 1998; 8: 115-117.
9. Mettler FA Jr, Williamson MR, Royal HD et al. Thyroid nodules in the population living around Chernobyl. JAMA 1992; 268: 616-619.
10. Anspaugh LR, Catlin RJ, Goldman M. The global impact of the Chernobyl reactor accident. Science 1988; 16(242): 1513-1519.
11. Pacini F, Vorontsova T, Molinaro E et al. Thyroid consequences of the Chernobyl nuclear accident. Acta Paediatr Suppl 1999; 88: 23-27.
12. Tronko MD, Bogdanova TI, Komissarenko IV et al. Thyroid carcinoma in children and adolescents in Ukraine after the Chernobyl nuclear accident: statistical data and clinicomorphologic characteristics. Cancer 1999; 86: 149-156.
13. Jacob P, Bogdanova TI, Buglova E et al. Thyroid cancer among Ukrainians and Belarusians who were children or adolescents at the time of the Chernobyl accident. J Radiol Prot 2006; 26: 51-67.
14. Bosetti C, Bertuccio P, Levi F et al. Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis. Ann Oncol 2008; 19: 631-640.
15. Dean DS, Gharib H. Epidemiology of thyroid nodules. Best Pract Res Clin Endocrinol Metab 2008; 22: 901-911.
16. Rago T, Vitti P. Role of thyroid ultrasound in the diagnostic evaluation of thyroid nodules. Best Pract Res Clin Endocrinol Metab 2008; 226: 913-928.
17. Pacini F, Schlumberger M, Dralle H et al. European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803.
18. Cooper DS, Doherty GM, Haugen BR et al. American Thyroid Association Guidelines Taskforce. The American Thyroid Association Guidelines Taskforce Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16: 109-142.
19. Baloch ZW, LiVolsi VA. Fine-needle aspiration of the thyroid: today and tomorrow. Best Pract Res Clin Endocrinol Metab 2008; 22: 929-39.
20. Nikiforov YE, Steward DL, Robinson-Smith TM et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009; 94: 2092-2098.
21. Elisei R, Bottici V, Luchetti F et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004; 89: 163-168.
22. Pacini F, Ladenson PW, Schlumberger M et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol 2006; 91: 926-932.
23. Pilli T, Brianzoni E, Capoccetti F et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007; 92: 3542-3546.
24. Cancer Staging Manual. 6th edition. American Joint Committee on Cancer: AJCC, New York, USA: Springer 2002.
25. Tuttle RM. Risk-adapted management of thyroid cancer. Endocr Pract 2008; 14: 764-774.
26. Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 2005; 90: 5047-5057.
27. Castagna MG, Brilli L, Pilli T et al. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab 2008; 93: 76-81.
28. Iervasi A, Iervasi G, Ferdeghini M et al. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin Endocrinol 2007; 67: 434-441.
29. Smallridge RC, Meek SE, Morgan MA et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 2007; 92: 82-87.
30. Schlumberger M, Hitzel A, Toubert ME et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab 2007; 92: 2487-2495.
31. Robbins RJ, Wan Q, Grewal RK et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006; 91: 498-505.
32. Feine U, Lietzenmayer R, Hanke JP et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996; 37: 1468-1472.
33. Wang W, Macapinlac H, Larson SM et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 2000; 85: 2082-2083.
34. Dietlein M, Scheidhauer K, Voth E et al. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997; 24: 1342-1348.
35. Durante C, Haddy N, Baudin E et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91: 2892-2899.
36. Sherman SI, Wirth LJ, Droz JP et al. for the Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008; 359: 31-42.
37. Ezra EW Cohen, Lee S et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study J Clin Onc 2008; 28: 4708-4713.
38. Pennell NA, Daniels GH, Haddad RI et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 2008; 18: 317-323.
39. Gupta-Abramson V, Troxel AB, Nellore A et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26: 4714-4719.
40. Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 2005; 1: 32-40.
41. Jemal A, Murray T, Ward E et al. Cancer statistics. CA Cancer J Clin 2005; 55: 10-30.
42. Schlumberger MJ, Elisei R, Bastholt L et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009; Jun 29.
43. Kober F, Hermann M, Handler A, Krotla G. Effect of sorafenib in symptomatic metastatic medullary thyroid cancer. J Clin Oncol 2007; 25: 14065.
44. Kebebew E, Greenspan FS, Clark OH et al. Anaplastic thyroid carcinoma: treatment outcome and prognostic factors. Cancer 2005; 1(103): 1330-1335.
45. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009; 16: 17-44.
46. Cantare S, Capezzone M, Marchisotta S, Capuano S, Busanero G, Toti P, Di Santo A, Caruso G, Carli AF, Brilli L, Montanaro A, Pacini F. Impact of protooncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Endocrinal Metab 2010; 95(3): 1365-1369.